Terug
Dagbereik
€ 34,20
€ 34,69
52-Weeksbereik
€ 33,51
€ 44,89
Volume
277
50D / 200D Gem.
€ 39,52
/
€ 40,93
Vorige Slotkoers
€ 34,24
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 1,3 | 0,4 |
| P/B | 0,6 | 2,9 |
| ROE % | 48,1 | 3,7 |
| Net Margin % | 6,3 | 3,9 |
| Rev Growth 5Y % | 7,6 | 10,0 |
| D/E | 1,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 0,00
€ 0,00 – € 0,00
|
56 B | 0 |
| FY2026 |
€ 0,00
€ 0,00 – € 0,00
|
52 B | 0 |
Belangrijkste Punten
Revenue grew 7,58% annually over 5 years — modest growth
ROE of 48,10% indicates high profitability
Generating 4,15B in free cash flow
P/E of 1,30 — trading at a low valuation
PEG of 0,43 suggests growth is underpriced
Cash machine — converts 131,53% of earnings into free cash flow
Groei
Revenue Growth (5Y)
7,58%
Revenue (1Y)10,07%
Earnings (1Y)11,23%
FCF Growth (3Y)32,06%
Kwaliteit
Return on Equity
48,10%
ROIC25,22%
Net Margin6,31%
Op. Margin9,12%
Veiligheid
Debt / Equity
0,98
Current Ratio1,11
Interest Coverage12,85
Waardering
P/E Ratio
1,30
P/B Ratio0,60
EV/EBITDA1,66
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10,07% | Revenue Growth (3Y) | 9,62% |
| Earnings Growth (1Y) | 11,23% | Earnings Growth (3Y) | 11,52% |
| Revenue Growth (5Y) | 7,58% | Earnings Growth (5Y) | 14,47% |
| Profitability | |||
| Revenue (TTM) | 50,01B | Net Income (TTM) | 3,16B |
| ROE | 48,10% | ROA | 14,01% |
| Gross Margin | 25,49% | Operating Margin | 9,12% |
| Net Margin | 6,31% | Free Cash Flow (TTM) | 4,15B |
| ROIC | 25,22% | FCF Growth (3Y) | 32,06% |
| Safety | |||
| Debt / Equity | 0,98 | Current Ratio | 1,11 |
| Interest Coverage | 12,85 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 1,30 | P/B Ratio | 0,60 |
| P/S Ratio | 0,08 | PEG Ratio | 0,43 |
| EV/EBITDA | 1,66 | Dividend Yield | 0,02% |
| Market Cap | 4,09B | Enterprise Value | 7,58B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 50,01B | 45,44B | 41,62B | 39,59B | 37,34B |
| Net Income | 3,16B | 2,84B | 2,54B | 2,64B | 1,84B |
| EPS (Diluted) | 39,32 | 23,84 | 20,84 | 21,60 | 14,88 |
| Gross Profit | 12,75B | 10,63B | 9,31B | 8,43B | 7,27B |
| Operating Income | 4,56B | 4,17B | 3,62B | 3,65B | 2,90B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 22,52B | 20,82B | 19,03B | 17,86B | 17,17B |
| Total Liabilities | 15,69B | 14,53B | 13,07B | 12,17B | 12,37B |
| Shareholders' Equity | 6,84B | 6,29B | 5,96B | 5,70B | 4,81B |
| Total Debt | 6,73B | 3,79B | 3,24B | 3,10B | 2,92B |
| Cash & Equivalents | 3,25B | 2,70B | 2,46B | 2,01B | 2,21B |
| Current Assets | 14,20B | 12,89B | 11,83B | 11,37B | 11,24B |
| Current Liabilities | 12,77B | 11,83B | 10,80B | 9,93B | 10,20B |
Strategiescores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026